Afleveringen
-
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
-
Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
-
Zijn er afleveringen die ontbreken?
-
Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
-
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
-
Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
-
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
-
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
-
David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
-
残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします！！
-
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
-
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！
-
Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
-
Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
-
Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
-
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
-
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
-
JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
- Laat meer zien
